Adverse events of albendazole due to mass drug administration


  • Pooja Agrawal Department of Pharmacology, Dr Susheela Tiwari Government Medical College and hospital, Haldwani, Uttarakhand, India
  • Bhavana Srivastava Department of Pharmacology, Dr Susheela Tiwari Government Medical College and hospital, Haldwani, Uttarakhand, India
  • Reena Bhardwaj Department of Pharmacology, Dr Susheela Tiwari Government Medical College and hospital, Haldwani, Uttarakhand, India
  • Sanjay Gaur Department of Pharmacology, Dr Susheela Tiwari Government Medical College and hospital, Haldwani, Uttarakhand, India



Albendazole, Adverse events, De-worming programme, Mass drug administration


Background: Soil-transmitted helminths are mostly prevalent in developing countries due to poor sanitation and lack of adequate clean water. The present study examines adverse events (AEs) experienced following administration of albendazole to children (2-19 Years) at Uttarakhand on national de-worming day.

Methods: Children were given single doses of albendazole on national de-worming day. Some of children experienced adverse events and were admitted in hospital of Govt Medical college Haldwani (Uttarakhand). Data were collected and analyzed.

Results: Total twenty five children were admitted due to albendazole adverse events. Out of these 92% were female. Mean age of admitted children was 14.14 years with standard deviation 3.45. Mean onset of adverse events was 5.6 hours with standard deviation of 1.5 hours. All children were treated symptomatically and were discharged once they recovered. No fatality due to adverse events was observed. Average duration of stay in hospital was 3.4 days. Out of twenty five children 12% children reported four or more adverse events, 40% children reported three adverse events and 48% reported two adverse events. Out AEs, 33% AEs were mild, 19% AEs were moderate, 31% AEs were severe and 17% AEs were serious. Abdominal pain was reported by 76%, headache by 44%, loss of consciousness by 32%, vomiting by 28%, nausea by 16%, convulsions by 12%, rashes by 8%, fever by 8%, and breathlessness by 14% and vertigo by 4%.

Conclusions: The adverse events were mild to serious but transient, but all of them recovered after hospitalization. Therefore, it is imperative that mass drug administration programmes put in place surveillance measures in order to ensure timely detection, management and reporting of potential life threatening AEs.


Steinmann P, Du ZW, Wang LB, Wang XZ, Jiang JY. Extensive multiparasitism in a village of Yunnan province, People's Republic of China, revealed by a suite of diagnostic methods. Am J Trop Med Hyg. 2008;78:760-9.

Steinmann P, Utzinger J, Du ZW, Zhou XN. Multiparasitism: a neglected reality on global, regional and local scale. Adv Parasitol. 2010;73:21-50.

Pullan R, Brooker S. The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases? Parasitology. 2008;135:783-94.

Willingham AL, Engels D. Control of Taenia solium cysticercosis/taeniosis. Adv Parasitol. 2006;61:509-66.

Craig P, Ito A. Intestinal cestodes. Curr Opin Infect Dis. 2007;20:524-32.

Ezeamama AE, Friedman JF, Olveda RM, Acosta LP, Kurtis JD, et al. Functional significance of low-intensity polyparasite helminth infections in anemia. J Infect Dis. 2005;192:2160-70.

Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich Sachs S, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357:1018-27.

Brooker S, Hotez PJ, Bundy DAP. Hookworm-related anaemia among pregnant women: a systematic review. PLoS Negl Trop Dis. 2008;2:e291.

Garcia HH, Moro PL, Schantz PM. Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. Curr Opin Infect Dis. 2007;20:489-94.

WHO. Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006:1-62.

Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet. 2009;373:1570-5.

Montresor A, Palmer K. Taeniasis/cysticercosis trend worldwide and rationale for control. Parasitol Int. 2006;55:S301-3.

OIE/WHO/FAO. WHO/FAO/OIE guidelines for the surveillance, prevention and control of taeniasis/cysticercosis; In: Murrell KD, editor. Paris: World Organization for Animal Health. 2005:1-139.

Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA. 2008;299:1937-48.

Horton J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr Opin Infect Dis. 2002;15:599-608.

Chavarria AP, Swartzwelder JC, Villarejos VM, Zeledon R. Mebendazole, an effective broad-spectrum anthelmintic. The American journal of tropical medicine and hygiene. 1973 Sep;22(5):592-5.

Geary TG, Woo K, McCarthy JS, Mackenzie CD, Horton J, et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010;40:1-13.

Albonico M, Allen H, Chitsulo L, Engels D, Gabrielli AF, et al. Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy. PLoS Negl Trop Dis. 2008;2:e126.

World Health Organization. Assuring safety of preventive chemotherapy interventions for the control of neglected tropical diseases; 2011:1-54.

Njomo DW, Tomono N, Ng’ethe M, Mitsui Y, Josyline KC, Mwandawiro CS. The adverse effects of albendazole and praziquantel in mass drug administration by trained schoolteachers. Afr J Health Sci. 2010;16:10-4.

Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. European Journal of Clinical Pharmacology. 1986;30:705-8.

Urbani C, Albendazoleonico M. Anthelminthic drug safety and drug administration in the control of soil transmitted helminthiasis in community campaigns. Acta Tropica. 2003;86:215-21.

Flisser A, Madrazo I, Plancarte A. Neurological symptoms in occult neurocysticercosis after single taeniacidal dose ofpraziquantel. Lancet. 1993;342:748.

Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. 2000;121:S113-32.

Garcia HH. Isidro Gonzalez Neurocysticercosis Uncovered by Single-Dose Albendazole (Letter to Editor). N Engl J Med. 2007;356;12:1277.




How to Cite

Agrawal, P., Srivastava, B., Bhardwaj, R., & Gaur, S. (2017). Adverse events of albendazole due to mass drug administration. International Journal of Basic & Clinical Pharmacology, 6(7), 1674–1677.



Original Research Articles